Table 3.
2006 | 2007 and 2008 | 2006 | 2007 and 2008 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Covered |
Not Covered |
P-value | Covered |
Not Covered |
P-value |
No PA or Step |
PA or Step |
P-value |
No PA or Step |
PA or Step |
P-Value | |
Adj. Rate |
Adj. Rate |
Adj. Rate |
Adj. Rate |
Adj. Rate |
Adj. Rate |
Adj. Rate |
Adj. Rate |
|||||
ARBs | ||||||||||||
Change | 0.11 | 0.35 | <0.0001* | 0.06 | 0.30 | <0.0001* | 0.11 | 0.35 | <0.0001* | 0.08 | 0.09 | 0.54 |
Gap | 0.21 | 0.30 | <0.0001* | 0.18 | 0.36 | <0.0001* | 0.20 | 0.38 | <0.0001* | 0.18 | 0.22 | 0.03 |
Cholinesterase Inhibitors | ||||||||||||
Change | 0.06 | 0.12 | <0.0001* | 0.05 | 0.17 | <0.0001* | 0.07 | 0.06 | 0.02 | 0.05 | 0.12 | <0.0001* |
Gap | 0.24 | 0.35 | <0.0001* | 0.17 | 0.22 | 0.31 | 0.22 | 0.35 | <0.0001* | 0.17 | 0.18 | 0.70 |
Opioids | ||||||||||||
Change | 0.24 | 0.32 | 0.0002 | 0.17 | 0.39 | 0.02 | 0.25 | 0.20 | 0.004 | 0.17 | 0.15 | 0.39 |
Gap | 0.27 | 0.41 | <0.0001* | 0.22 | 0.27 | 0.52 | 0.28 | 0.28 | 0.99 | 0.22 | 0.23 | 0.46 |
Osteoporosis Medications | ||||||||||||
Change | 0.18 | 0.40 | <0.0001* | 0.05 | 0.79 | 0.0001* | 0.18 | 0.29 | <0.0001* | 0.05 | 0.15 | <0.0001* |
Gap | 0.33 | 0.40 | 0.26 | 0.24 | 0.55 | 0.02 | 0.33 | 0.38 | 0.01 | 0.24 | 0.23 | 0.47 |
Anti-depressants | ||||||||||||
Change | 0.20 | 0.37 | <0.0001* | 0.13 | 0.48 | <0.0001* | 0.21 | 0.24 | 0.03 | 0.13 | 0.17 | 0.0002 |
Gap | 0.18 | 0.22 | <0.0001* | 0.15 | 0.32 | <0.0001* | 0.18 | 0.20 | 0.20 | 0.15 | 0.16 | 0.61 |
Anti-psychotics | ||||||||||||
Change | 0.14 | 0.22 | 0.02 | -- | -- | -- | 0.14 | 0.14 | 0.84 | 0.09 | 0.17 | <0.0001* |
Gap | 0.25 | 0.35 | 0.03 | -- | -- | -- | 0.26 | 0.24 | 0.07 | 0.20 | 0.22 | 0.16 |
Results that remain statistically significant after correcting for multiple comparisons using the Bonferroni correction.
Notes: Prior authorization and step therapy are only required for covered drugs, so we assess whether prior authorization or step therapy was required conditional on plan coverage. We were unable to estimate models for atypical antipsychotic users in 2007/2008 due to a very small number of individuals whose atypical antipsychotic medication was not covered by their new plan.